Overview

Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

This is a pilot, proof of concept study to evaluate the safety and efficacy of ALZ-1101 dosed once daily for 28 days compared to latanoprost 0.005% ophthalmic solution in patients with elevated intraocular pressure not adequately controlled with latanoprost.

Phase:

Phase 2

Details

Lead Sponsor:

Alleanza Pharmaceuticals, Inc.

Treatments:

Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions